Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimer's Disease
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- SAMP8 mice, a strain that ages fast and is used as a model of Alzheimer's disease, with control mice. About 4 animals in each group.
- Dose used in the study
- 5 mg/kg a day by mouth
- Duration
- 2 months, from 4 months of age
- What was measured
- Contractions of the colon, build-up of amyloid and alpha-synuclein in the gut, inflammatory markers, gut barrier proteins and bacterial toxin in the blood
What the authors reported
Treated mice had stronger colon contractions (19.46 against 8.98 g per g of tissue), less amyloid in the colon, lower IL-1 beta, and less bacterial toxin in the blood (25.85 against 67.8 ng/mL).
Limits of this study
A mouse study with about four animals in each group, in one strain at an early stage. The authors note that they did not study later stages or sex differences. It does not show an effect in patients. It was funded by the University of Pisa, and the authors declared no conflicts.
Source
Entry checked against the full text at the publisher (Frontiers) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.